Skip Navigation

Find a Doctor

Find a Researcher

Researchers

Emmanuel Stylianos Antonarakis, M.B.B.Ch.

Photo of Dr. Emmanuel Stylianos Antonarakis, M.B.B.Ch.
  • Professor of Oncology
Male

Languages: English, French, Greek

Expertise

Medical Oncology, Prostate Cancer, Urological Oncology

Research Interests

Prostate cancer clinical trials; Prostate cancer biomarker development; AR-V7 biomarker; Androgen receptor-targeted therapy; Immunotherapy; Genomics

Request an Appointment

Insurance Information

Maryland

410-955-8964
Request Appointment

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway Baltimore, MD 21231 map
Phone: 443-287-0553 | Fax: 410-614-8397

Skip Viragh Outpatient Cancer Center

Appointment Phone: 410-955-8893
201 N. Broadway Baltimore, MD 21287 map
Fax: 410-614-7287

Background

Dr. Antonarakis is a Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He obtained his medical degree from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a Residency in Internal Medicine at the Johns Hopkins Bayview Medical Center, followed by a Fellowship in Medical Oncology at the Johns Hopkins Hospital. In 2010, he joined the Johns Hopkins faculty as an attending physician and translational researcher. Dr. Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies.

His research focuses on drug development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer, and using cancer genomics to inform precision oncology approaches. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 biomarker as well as DNA repair markers and their therapeutic implications. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 220 peer-reviewed articles, and several book chapters.

...read more

Titles

  • Professor of Oncology
  • Professor of Urology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MBBCh, University of Wales (2003)

Residencies

  • Johns Hopkins Bayview Medical Center / Internal Medicine (2007)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2010)

Board Certifications

  • American Board of Internal Medicine / Medical Oncology (2009)

Additional Training

  • Physician License, State of Maryland (2007)

Research & Publications

Research Summary

Dr. Antonarakis is a Professor of Oncology and Urology with an interest in genitourinary cancers and a particular focus on prostate cancer. He is an expert in the clinical management of patients with prostate cancer and other urological malignancies.

His research focuses on drug development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer, and using cancer genomics to inform precision oncology approaches. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 biomarker as well as DNA repair markers and their therapeutic implications. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 220 peer-reviewed articles, and several book chapters.

Lab

AR-V7 biomarker, Genomics

Clinical Trial Keywords

Prostate Cancer

Clinical Trials

Phase II and III clinical trials in prostate cancer

Selected Publications

View all on Pubmed

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371: 1028-1038.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015; 1: 582-591.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017; 35: 2149-2156.

Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein J, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018; 74: 218-225.

Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, Lotan TL. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2019; 75: 378-382.

Patents

Multiple novel androgen receptor variants as biomarkers and therapeutic targets for androgen-refractory human prostate cancer
Patent # C10305

Methods and compositions related to prostate cancer therapeutics
Patent # C13126

Activities & Honors

Honors

  • ASCO Young Investigator Award (2009), ASCO, 2009
  • PCF Young Investigator Award (2013), Prostate Cancer Foundation (PCF), 2013
  • SBUR/AUA Young Investigator Award (2015), Society for Basic Urologic Research of the AUA, 2015

Memberships

  • American Medical Association, 2004
  • American Society of Clinical Oncology, 2007
  • American Association for Cancer Research (AACR), 2007
  • Eastern Cooperative Oncology Group (ECOG), 2010
  • Prostate Cancer Clinical Trials Consortium (PCCTC), 2010
  • Society for Basic Urologic Research (SBUR) of the AUA, 2014

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button